Anxiolytic effects of maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 1, 2005, Pages 282-292

  Korsgaard, M P G ^a   Hartz, B P ^a   Brown, W D ^a   Ahring, P K ^a   Strobaek D ^a   Mirza, N R ^a  

^a NEUROSEARCH A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

10,10 BIS PYRIDIN 4 YLMETHYL 10H ANTHRACEN 9 ONE; 10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; CALCIUM ACTIVATED POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCNQ1; RETIGABINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY DISORDER; ARTICLE; ATAXIA; CALCIUM CONDUCTANCE; COGNITION; CONTROLLED STUDY; DRUG MECHANISM; ELECTROPHYSIOLOGY; EMBRYO; ENANTIOMER; EXPLORATORY BEHAVIOR; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NEUROMODULATION; NONHUMAN; OOCYTE; PATCH CLAMP; PERFORMANCE; PRIORITY JOURNAL; RAT; SEDATION; TRANQUILIZING ACTIVITY; XENOPUS;

ALGORITHMS; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ATAXIA; BEHAVIOR, ANIMAL; CARBAMATES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EMOTIONS; EXPLORATORY BEHAVIOR; FEMALE; HAND STRENGTH; INDOLES; KCNQ POTASSIUM CHANNELS; KCNQ1 POTASSIUM CHANNEL; MALE; MEMBRANE POTENTIALS; MICE; NEURONS; OOCYTES; PATCH-CLAMP TECHNIQUES; PHENYLENEDIAMINES; POTASSIUM CHANNELS, VOLTAGE-GATED; RATS; RATS, WISTAR; RECEPTORS, GABA-A; RNA, COMPLEMENTARY; STEREOISOMERISM; XENOPUS LAEVIS;

EID: 23044477292     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.083923     Document Type: Article

References (51)

1. + channel alpha- and beta-subunits in HEK293 cells. FEBS Lett 415:67-70.
2. Anand A and Shekhar A (2003) Brain imaging studies in mood and anxiety disorders: special emphasis on the amygdala. Ann NY Acad Sci 985:370-388.
3. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, and Steinlein OK (1998) A potassium channel mutation in neonatal human epilepsy. Science (Wash DC) 279:403-406.
4. Broekkamp CL, Rijk HW, Joly-Gelouin D, and Lloyd KL (1986) Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126:223-229.
5. + current in a vertebrate neurone. Nature (Lond) 283:673-676.
6. Davis M (1992) The role of the amygdala in fear and anxiety. Annu Rev Neurosci 15:353-375.
7. Dieter H-R, Engel J, Kutscher B, Polymeropoulos E, Szelenyi S, and Nickel B (1996) inventors, Asta Medica AG, assignee. 1,2,4-Triaminobenzene derivatives and process for their preparation. Patent GR3019653T. 1996 Jul 31.
8. Dunnett SB, Rogers DC, and Jones GH (1989) Effects of nucleus basalis magnocellularis lesions in rats on delayed matching and non-matching to position tasks. Eur J Neurosci 1:395-406.
9. Dupuis DS, Schrøder RL, Jespersen T, Christensen JK, Christophersen P, Jensen BS, and Olesen SP (2002) Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur J Pharmacol 437:129-137.
10. Earl RA, Myers MJ, and Nickolson VJ (1989) inventors, Du Pont Merck Pharma, assignee. Alpha, alpha-disubstituted aromatics and heteroaromatics as cognition enhancers. Patent 311010A2. 1989 December 4.
11. Earl RA, Zaczek R, Teleha CA, Fisher BN, Maciag CM, Marynowski ME, Logue AR, Tam SW, Tinker WJ, Huang SM, and Chorvat RJ (1998) 2-Fluoro-4- pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action. J Med Chem 41:4615-4622.
12. Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, and Troy S (2002) Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 42:175-182.
13. Green S (1991) Benzodiazepines, putative anxiolytics and animal models of anxiety. Trends Neurosci 14:101-104.
14. Gribkoff VK (2003) The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 7:737-748.
15. Gribkoff VK, Starrett JE Jr, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, Frantz SW, Heman K, Hibbard JR, Huston K, et al. (2001) Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med 7:471-477.
16. Grunnet M, Jespersen T, Rasmussen HB, Ljungstrøm T, Jørgensen NK, Olesen SP, and Klærke DA (2002) KCNE4 is an inhibitory subunit to the KCNQ1 channel. J Physiol 542:119-130.
17. Ilyin VI, Carlin KP, Hodges DD, Robledo S, and Woodward RM (2002) Flupirtine-a positive modulator of heteromeric KCNQ2/3 channels (Abstract). Soc Neurosci Abstr 758.10.
18. Irwin S (1969) Pre-clinical drug evaluation and method development. Psychopharmacol Bull 5:27-28.
19. A receptor. J Biol Chem 277:41438-41447.
20. + channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci USA 97:4333-4338.
21. Korsgaard MPG, Herrik KF, Brown WD, Christophersen P, and Strøbæk D (2003) Flupirtine activates KCNQ channels (Abstract). Biophys J S84:547a.
22. Lattal KA (1991) Scheduling positive reinforcers, in Experimental Analysis of Behaviour Part 1. Elsevier Science, B.V., Amsterdam.
23. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, and Burbidge SA (2000) Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58:253-262.
24. + conductance in acutely isolated pyramidal-like neurons from the rat basolateral amygdaloid complex. J Neurophysiol 78:1256-1262.
25. Pare D and Collins DR (2000) Neuronal correlates of fear in the lateral amygdala: multiple extracellular recordings in conscious cats. J Neurosci 20:2701-2710.
26. Passmore GM, Selyanko AA, Mistry M, Al Qatari M, Marsh SJ, Matthews EA, Dickenson AH, Brown TA, Burbidge SA, Main M, and Brown DA (2003) KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci 23:7227-7236.
27. Pendri YR, Martinez EJ, Thottathil JK, and Hewawasam P (1997) inventors, Squibb Bristol Myers Co., assignee. Preparation of 3-fluoro oxindole derivatives. U.S. patent WO9816222. 1998 Feb 24.
28. Racine RJ (1972) Modification of seizure activity by electrical stimulation. I. Afterdischarge threshold. Electroencephalogr Clin Neurophysiol 32:269-279.
29. Rauch SL, Shin LM, and Wright CI (2003) Neuroimaging studies of amygdala function in anxiety disorders. Ann NY Acad Sci 985:389-410.
30. Robbins J (2001) KCNQ potassium channels: physiology, pathophysiology and pharmacology. Pharmacol Ther 90:1-19.
31. Rosen JB and Schulkin J (1998) From normal fear to pathological anxiety. Psychol Rev 105:325-350.
32. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, Loscher W, Honack D, White HS, and Wolf HH (1996) D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures 9. Epilepsy Res 23:211-223.
33. Rundfeldt C and Netzer R (2000) Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 50:1063-1070.
34. + channels in brain. J Neurosci 21:4609-4624.
35. Schrøder RL, Jespersen T, Christophersen P, Strøbæk D, Jensen BS, and Olesen SP (2001) KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 40:888-898.
36. Schrøder RL, Strøbæk D, Olesen SP, and Christophersen P (2003) Voltageindependent KCNQ4 currents induced by (+/-)BMS-204352. Pflugers Arch 446:607-616.
37. Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, and Jentsch TJ (2000a) KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem 275:24089-24095.
38. Schroeder BC, Waldegger S, Fehr S, Bleich M, Warth R, Greger R, and Jentsch TJ (2000b) A constitutively open potassium channel formed by KCNQ1 and KCNE3. Nature (Lond) 403:196-199.
39. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, and Dourish CT (1994) Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology (Berl) 116:56-64.
40. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, et al. (1998) A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18:25-29.
41. Søgaard R, Ljungstrøm T, Pedersen KA, Olesen SP, and Jensen BS (2001) KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology 2. Am J Physiol 280:C859-C866.
42. Stanhope KJ and Dourish CT (1996) Effects of 5-HT1A receptor agonists, partial agonists and a silent antagonist on the performance of the conditioned emotional response test in the rat. Psychopharmacology (Berl) 128:293-303.
43. Steriade M and McCarley RW (1990) Brainstem Control of Wakefulness and Sleep. Plenum Publishing Corporation, New York.
44. Strøbæk D, Jørgensen TD, Christophersen P, Ahring PK, and Olesen SP (2000) Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol 129:991-999.
45. Sullivan GM, Apergis J, Gorman JM, and LeDoux JE (2003) Rodent doxapram model of panic: behavioral effects and c-Fos immunoreactivity in the amygdala. Biol Psychiatry 53:863-870.
46. Tatulian L, Delmas P, Abogadie FC, and Brown DA (2001) Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 21:5535-5545.
47. Ks channels to the cognitive enhancer XE991. Mol Pharmacol 57:1218-1223.
48. Womble MD and Moises HC (1992) Muscarinic inhibition of M-current and a potassium leak conductance in neurones of the rat basolateral amygdala. J Physiol 457:93-114.
49. Yang WP, Levesque PC, Little WA, Conder ML, Ramakrishnan P, Neubauer MG, and Blanar MA (1998) Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. J Biol Chem 273:19419-19423.
50. Yang WP, Levesque PC, Little WA, Conder ML, Shalaby FY, and Blanar MA (1997) KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias. Proc Natl Acad Sci USA 94:4017-4021.
51. Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, Fisher BN, Rominger DH, and Earl RA (1998) Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J Pharmacol Exp Ther 285:724-730.